ClinicalTrials.gg
RecruitingNCT06975982Updated May 29, 2025

Symptoms, Pulmonary Function, Muscle Strength, Exercise Capacity, and Frailty in Esophageal Atresia vs. Healthy Peers

An observational study in Esophageal Atresia and Healthy Children, sponsored by Hacettepe University. Recruiting at 1 site in Turkey. Open to participants aged 6 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-29.

Sponsored by Hacettepe University · Observational

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years later.
Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
20
Ages
6 Years to 18 Years
Sex
All
01

Study summary

Esophageal atresia is the most common congenital anomaly of the esophagus and is caused by abnormal development of the esophagus during intrauterine life. In children with esophageal atresia, structural abnormalities due to congenital anomalies and tracheoesophageal fistula, tracheomalacia, respiratory problems, recurrent respiratory tract infections, structural abnormalities, surgical interventions for repair and treatment, and decreased physical activity levels may negatively affect pulmonary function, effective coughing, muscle strength, exercise capacity, posture, motor function, and quality of life. This study aims to compare physical characteristics, body composition, pulmonary function and muscle strength, peak cough flow, posture assessment, peripheral muscle strength test, motor function, exercise capacity, physical activity level, fatigue, frailty and quality of life between children with esophageal atresia and their healthy peers.

02

Conditions studied

  • Esophageal Atresia
  • Healthy Children

Keywords

  • Esophageal atresia
  • Exercise capacity
  • Physical activity
  • Muscle strength
03

In context

Esophageal Atresia

37 studies on the registry are indexed under Esophageal Atresia; 12 are open to participants now.

This study's planned enrollment of 20 is below the median of 50 across 19 observational studies indexed under Esophageal Atresia.

Browse Esophageal Atresia studies →

Lead sponsor

Hacettepe University is the lead sponsor of 1,007 studies on the registry; 214 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Children with esophageal atresia and their healthy peers

Eligibility criteria

Esophageal atresia group

Inclusion Criteria:

  • Children with esophageal atresia who are willing to participate in the study
  • Being between the ages of 6-18,
  • Being able to cooperate with the assessments

Exclusion Criteria:

  • Being unable to cooperate with the assessments,
  • Having an orthopedic, neurological or cardiovascular problem that may affect the assessments,
  • Having a lung infection or upper respiratory tract infection in the last four weeks,
  • Being an active smoker,
  • Not being willing to participate in the study,

Control group

Inclusion Criteria:

  • Being between the ages of 6-18,
  • Being willing to cooperate with the tests to be performed,
  • Being willing to participate in the study.

Exclusion Criteria:

  • Having a musculoskeletal problem that may affect exercise performance,
  • Having any known chronic disease,
  • Having a lung infection or upper respiratory tract infection in the last four weeks,
  • Being an active smoker,
  • Not willing to participate in the study.
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
20 participants (estimated)
Patient registry
No

Groups and cohorts

  • Children with esophageal atresia

    Children with esophageal atresia

    Other: No intervention

  • Healthy children

    Healthy children

    Other: No intervention

Interventions

  • OtherNo intervention

    No intervention

06

What researchers measure

Primary outcomes

  1. Forced vital capacity

    Pulmonary function test using a spirometer will be performed. Forced vital capacity will be recorded.

    Time frame: 1st day

  2. Forced expiratory volume in one second

    Pulmonary function test using a spirometer will be performed. Forced expiratory volume in one second will be recorded.

    Time frame: 1st day

  3. Forced expiratory volume in one second/forced vital capacity ratio

    Pulmonary function test using a spirometer will be performed. Forced expiratory volume in one second/forced vital capacity ratio will be recorded.

    Time frame: 1st day

  4. Peak expiratory flow

    Pulmonary function test using a spirometer will be performed. Peak expiratory flow will be recorded.

    Time frame: 1st day

  5. Forced mid-expiratory flow

    Pulmonary function test using a spirometer will be performed. Forced mid-expiratory flow (FEF25-75) will be recorded.

    Time frame: 1st day

  6. Body composition

    Body composition will be evaluated by triceps skinfold thickness. Skinfold caliper will be used to evaluate triceps skinfold thickness.

    Time frame: 1st day

  7. Maximal inspiratory pressure

    Maximal inspiratory pressure will be measured using an mouthpiece pressure measuring device.

    Time frame: 1st day

  8. Maximal expiratory pressure

    Maximal expiratory pressure will be measured using an mouthpiece pressure measuring device.

    Time frame: 1st day

  9. Peak cough flow

    Peak cough flow will be measured using a peak flow meter.

    Time frame: 1st day

  10. Hand grip strength

    Hand grip strength will be evaluated with a hand dynamometer device.

    Time frame: 1st day

  11. Knee extensor muscle strength

    Knee extensor muscle strength will be assessed with a portable digital dynamometer.

    Time frame: 1st day

  12. Shoulder abductor muscle strength

    Shoulder abductor muscle strength will be assessed with a portable digital dynamometer.

    Time frame: 1st day

  13. Motor function

    Motor function will be assessed using Time Up and Go test. In the Time Up and Go test, the individual is asked to stand up from a standard chair with armrests, walk 3 m, turn, walk back to the chair, and sit down again. The time is recorded in seconds.

    Time frame: 1st day

  14. Functional exercise capacity

    6 minute walk test will be performed to assess functional capacity.

    Time frame: 1st day

  15. Physical activity level

    The Physical Activity Questionnaire for Children (PAQ-C) and the Physical Activity Questionnaire for Adolescents (PAQ-A) will be used to assess physical activity levels. The Turkish versions of these assessment tools have been shown to be valid and reliable. The total score ranges from 1 to 5, where 1 indicates very low physical activity, 5 indicates very high physical activity levels.

    Time frame: 1st day

  16. Exercise capacity

    To assess exercise capacity, a symptom-limited cardiopulmonary exercise test will be performed on a bicycle ergometer using Bruce protocol.

    Time frame: 1 week after other assessments

  17. Frailty

    Frailty level will be calculated using the Composite Frailty Score: (1) Slowness: 6 minute walk test, (2) Weakness: handgrip strength, (3) Fatigue: Pediatric Quality of Life (PedsQL) Multidimensional Fatigue Scale (PedsQL-MFS), (4) Body composition: triceps skinfold thickness, and (5) Physical activity questionnaire. Each domain is scored on a 0-5 point scale, using z-scores or raw questionnaire scores to assign frailty points (0 = least frail, 5 = most frail). The five domain scores is summed to generate a Composite Frailty Score ranging from 0 to 25, where higher scores reflect greater frailty.

    Time frame: 1st day

Secondary outcomes

  1. Quality of life assessment

    Quality of life will be assessed using Esophageal-Atresia-Quality of Life (EA-QOL) questionnaire. The EA-QOL questionnaire consist of a 17-item parent-reported questionnaire for children aged 2-7 years (eating, physical health and treatment, social isolation, and stress) and a 24-item questionnaire available as child- and parent-reported versions for children aged 8-17 years (eating, social relationships, body image, and health and well-being). Scores range from 0 to 100. Higher scores indicate better quality of life.

    Time frame: 1st day

  2. Fatigue

    Fatigue will be assessed using the Pediatric Quality of Life Multidimensional Fatigue Scale (PedsQL-MFS). The PedsQL-MFS allows the child to assess their own fatigue and parents to assess their child's fatigue. The higher the score, the better the quality of life, indicating fewer fatigue symptoms. Therefore, a score of "0" on the PedsQL-MFS indicates greater fatigue, while a score of "100" indicates less fatigue.

    Time frame: 1st day

  3. Corbin Posture Rating Scale

    Corbin Posture Rating Scale and observational posture analysis. It is an assessment consisting of lateral and posterior posture analysis. '0' is excellent, 12 and above indicates poor posture.

    Time frame: 1st day

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2024 (actual). Primary completion is estimated for Oct 2027, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2025
First posted
May 16, 2025
StartActual
Oct 24, 2024
Primary completionEst.
Oct 24, 2027
CompletionEst.
Oct 24, 2027
Last update
May 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06975982
Responsible party
Aslihan Cakmak-Onal (Principal Investigator, Hacettepe University) — Principal investigator
First posted
May 16, 2025
Start date
Oct 24, 2024
Primary completion
Oct 24, 2027 (estimated)
Completion
Oct 24, 2027 (estimated)
Last update
May 29, 2025

Study contacts

Aslihan Cakmak-Onal, PhD, PT
Contact
aslihancakmak90@gmail.com
+90 312 305 15 76
Deniz Inal-Ince, PhD, PT
study director · Hacettepe University
Tutku Soyer, MD
study chair · Hacettepe University
Özlem Boybeyi Turer, MD
study chair · Hacettepe University
Elmas Ebru Yalcin, MD
study chair · Hacettepe University
Nagehan Emiralioglu-Ordukaya, MD
study chair · Hacettepe University
Meltem Yildiz-Kayaoglu, MD
principal investigator · Hacettepe University
Ismail Songul, MD
principal investigator · Hacettepe University
Elif Kocaaga, MSc, PT
principal investigator · Hacettepe University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion